Preliminary data also show that68Gallium-PSMA ligand PET/CT may be beneficial for biopsy targeting after a previous negative biopsy in a patient highly suspected of having prostate cancer, especially when combined with mpMRI28. This evidence concerns the gene FOLH1 and prostate carcinoma.